A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
NCT ID: NCT06830629
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
56 participants
INTERVENTIONAL
2025-02-05
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MZE829
Cohort 1: Chronic kidney disease with concurrent diabetes
Cohort 2: Chronic kidney disease without concurrent diabetes
MZE829
Capsules for oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MZE829
Capsules for oral administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic kidney disease with persistent albuminuria
Exclusion Criteria
* History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
* Conditions that may alter drug absorption, e.g., history of bariatric surgery
* Type I diabetes
* Pregnant or currently nursing
18 Years
68 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maze Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Maze Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Decatur, Alabama, United States
Research Site
Huntsville, Alabama, United States
Research Site
Montgomery, Alabama, United States
Research Site
Granada Hills, California, United States
Research Site
Valencia, California, United States
Research Site
Bloomfield, Connecticut, United States
Research Site
Atlantis, Florida, United States
Research Site
Brandon, Florida, United States
Research Site
Brooksville, Florida, United States
Research Site
Hollywood, Florida, United States
Research Site
Melbourne, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
College Park, Georgia, United States
Research Site
Cordele, Georgia, United States
Research Site
Macon, Georgia, United States
Research Site
Savannah, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Bowling Green, Kentucky, United States
Research Site
Louisville, Kentucky, United States
Research Site
Baltimore, Maryland, United States
Research Site
Lutherville, Maryland, United States
Research Site
Oxon Hill, Maryland, United States
Research Site
Dearborn, Michigan, United States
Research Site
Flint, Michigan, United States
Research Site
Pontiac, Michigan, United States
Research Site
Saint Joseph, Michigan, United States
Research Site
Shelby, Michigan, United States
Research Site
Minneapolis, Minnesota, United States
Research Site
Fayette, Mississippi, United States
Research Site
Ridgeland, Mississippi, United States
Research Site
Tupelo, Mississippi, United States
Research Site
City of Saint Peters, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Laurelton, New York, United States
Research Site
Maspeth, New York, United States
Research Site
New York, New York, United States
Research Site
Durham, North Carolina, United States
Research Site
Greensboro, North Carolina, United States
Research Site
Shelby, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
Research Site
Ardmore, Oklahoma, United States
Research Site
Upland, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Spartanburg, South Carolina, United States
Research Site
Spartanburg, South Carolina, United States
Research Site
Chattanooga, Tennessee, United States
Research Site
Greenville, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Houston, Texas, United States
Research Site
McKinney, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Shenandoah, Texas, United States
Research Site
Sherman, Texas, United States
Research Site
Hampton, Virginia, United States
Research Site
Norfolk, Virginia, United States
Research Site
Créteil, , France
Research Site
Lyon, , France
Research Site
Paris, , France
Research Site
Paris, , France
Research Site
Saint-Ouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MZE829-201
Identifier Type: -
Identifier Source: org_study_id